Cargando…
Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE)
BACKGROUND: Inhibitor development is the most serious treatment-related complication of replacement coagulation factor VIII (FVIII) therapy for patients with haemophilia A. Immune tolerance induction (ITI), which involves intensive and prolonged treatment with plasma-derived or recombinant FVIII, is...
Autores principales: | Escuriola Ettingshausen, Carmen, Sidonio, Robert F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474305/ https://www.ncbi.nlm.nih.gov/pubmed/34589194 http://dx.doi.org/10.1177/20406207211032452 |
Ejemplares similares
-
octanate(®): over 20 years of clinical experience in overcoming challenges in haemophilia A treatment
por: Klukowska, Anna, et al.
Publicado: (2020) -
The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
por: Carcao, Manuel, et al.
Publicado: (2019) -
3α-Hydroxy-ent-atis-16-en-14-one
por: Wang, Huan, et al.
Publicado: (2009) -
Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
por: Dargaud, Yesim, et al.
Publicado: (2021) -
High INtensity Interval Training In pATiEnts with intermittent claudication (INITIATE): protocol for a multicentre, proof-of-concept, prospective interventional study
por: Pymer, Sean, et al.
Publicado: (2020)